Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 4
2007 16
2008 16
2009 8
2010 15
2011 12
2012 15
2013 21
2014 23
2015 14
2016 11
2017 14
2018 10
2019 7
2020 6
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

176 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Locatelli F, et al. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16. Clin J Am Soc Nephrol. 2019. PMID: 31420350 Free PMC article. Clinical Trial.
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta with those of the shorter-acting agents epoetin alfa/beta and darbepoetin alfa in patients with anemia of …
We compared cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoe
Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.
Curran MP, McCormack PL. Curran MP, et al. Drugs. 2008;68(8):1139-56. doi: 10.2165/00003495-200868080-00009. Drugs. 2008. PMID: 18484803 Review.
Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin receptor activator, with a long half-life (approximately 130 hours). ...Methoxy polyethylene glycol-epoetin
Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin recept
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N, Awaisu A. Alsalimy N, et al. Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7. Int J Clin Pharm. 2014. PMID: 25288147 Review.
Different reviews have focused on evaluating the safety and efficacy of methoxy polyethylene glycol-epoetin beta (MPG-EPO), a continuous erythropoietin receptor activator, in CKD patients regardless of dialysis depend …
Different reviews have focused on evaluating the safety and efficacy of methoxy polyethylene glycol-epoetin b
Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.
Schmid H. Schmid H. Expert Rev Hematol. 2016 Jan;9(1):5-20. doi: 10.1586/17474086.2016.1112734. Epub 2015 Nov 17. Expert Rev Hematol. 2016. PMID: 26573694 Review.
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney disease. Methoxy polyethylene glycol-epoetin beta (MPG-EPO), also called continuous erythropoietin
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney dis …
Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.
Kacarska-Fotevska II, Volckova N, Ilievska K, Donev D. Kacarska-Fotevska II, et al. Med Arch. 2020 Apr;74(2):109-114. doi: 10.5455/medarh.2020.74.109-114. Med Arch. 2020. PMID: 32577051 Free PMC article.
Erythropoiesis-stimulating agent (ESA) is a standard therapy for renal anemia, but management of anemia in CKD still remains a challenge from the treatment point of view. AIM: To evaluate safety and efficacy of methoxy polyethylene glycol-epoetin be
Erythropoiesis-stimulating agent (ESA) is a standard therapy for renal anemia, but management of anemia in CKD still remains a challenge fro …
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Palmer SC, et al. Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2. Cochrane Database Syst Rev. 2014. PMID: 25486075 Free PMC article. Review.
SELECTION CRITERIA: Randomised controlled trials (RCTs) that included a comparison of an ESA (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, or biosimilar ESA) with another ESA, place …
SELECTION CRITERIA: Randomised controlled trials (RCTs) that included a comparison of an ESA (epoetin alfa, epoetin beta
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Saglimbene VM, et al. Cochrane Database Syst Rev. 2017 Aug 7;8(8):CD009904. doi: 10.1002/14651858.CD009904.pub2. Cochrane Database Syst Rev. 2017. PMID: 28782299 Free PMC article. Review.
BACKGROUND: Continuous erythropoiesis receptor activator (CERA) is a newer, longer acting ESA which might be preferred to other ESAs (epoetin or darbepoetin) based on its lower frequency of administration. ...One study compared CERA with placebo, nine …
BACKGROUND: Continuous erythropoiesis receptor activator (CERA) is a newer, longer acting ESA which might be preferred …
Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
Schmidt RJ. Schmidt RJ. Expert Opin Pharmacother. 2009 Jun;10(9):1509-14. doi: 10.1517/14656560902997982. Expert Opin Pharmacother. 2009. PMID: 19505218 Review.
OBJECTIVES: To review the option of methoxy polyethylene glycol-epoetin beta for ESA therapy in patients with renal anemia. METHODS: Peer-reviewed scientific literature, published abstracts and renal business journals were reviewed in the writin …
OBJECTIVES: To review the option of methoxy polyethylene glycol-epoetin beta for ESA therapy in patients …
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B, Mariusz S, Jacek R. Piotr B, et al. Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801. Curr Pharm Biotechnol. 2017. PMID: 28137221 Review.
Literature data indicate the usefulness of long-acting ESAs in treatment of anemia in non-dialysis CKD patients. In particular, continuous erythropoietin receptor activator seems to be a good choice in these patients because of its efficiency, safety a …
Literature data indicate the usefulness of long-acting ESAs in treatment of anemia in non-dialysis CKD patients. In particular, continuou
[Switch of methoxy-polyethylene-glycol-epoetin beta to darbepoetin alfa in 263 dialysis patients].
Rieger J, Krummel T, Petitjean P, Chantrel F, Dimitrov Y. Rieger J, et al. Ann Pharm Fr. 2016 Jan;74(1):45-8. doi: 10.1016/j.pharma.2015.06.005. Epub 2015 Jul 17. Ann Pharm Fr. 2016. PMID: 26194063 French.
In early 2012, due to national supply disruption, the methoxy-polyethylene glycol-epoetin beta (CERA) was no longer available and has been replaced by darbepoetin alfa (DA) in all dialysis patients. ...
In early 2012, due to national supply disruption, the methoxy-polyethylene glycol-epoetin beta (CERA) was …
176 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page